Mortality in Escherichia coli bloodstream infections: antibiotic resistance still does not make it
出版年份 2020 全文链接
标题
Mortality in Escherichia coli bloodstream infections: antibiotic resistance still does not make it
作者
关键词
-
出版物
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2020-04-14
DOI
10.1093/jac/dkaa161
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Colistin resistance in Parisian inpatient faecal Escherichia coli as the result of two distinct evolutionary pathways
- (2019) Anne Sophie Bourrel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance
- (2018) Patrick N. A. Harris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Trends over time in Escherichia coli bloodstream infections, urinary tract infections, and antibiotic susceptibilities in Oxfordshire, UK, 1998–2016: a study of electronic health records
- (2018) Karina-Doris Vihta et al. LANCET INFECTIOUS DISEASES
- Impact of host-pathogen-treatment tripartite components on early mortality of patients with Escherichia coli bloodstream infection: Prospective observational study
- (2018) Eun-Jeong Yoon et al. EBioMedicine
- Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis
- (2018) Alessandro Cassini et al. LANCET INFECTIOUS DISEASES
- Global epidemiology of CTX-M β-lactamases: temporal and geographical shifts in genotype
- (2017) Edward R. Bevan et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- PHYLOViZ 2.0: providing scalable data integration and visualization for multiple phylogenetic inference methods
- (2016) Marta Nascimento et al. BIOINFORMATICS
- Two levels of specialization in bacteraemic Escherichia coli strains revealed by their comparison with commensal strains
- (2016) O. CLERMONT et al. EPIDEMIOLOGY AND INFECTION
- Thirty day all-cause mortality in patients with Escherichia coli bacteraemia in England
- (2015) J.K. Abernethy et al. CLINICAL MICROBIOLOGY AND INFECTION
- Marked increase in incidence for bloodstream infections due to Escherichia coli, a side effect of previous antibiotic therapy in the elderly
- (2015) Nathalie L. van der Mee-Marquet et al. Frontiers in Microbiology
- Ragout--a reference-assisted assembly tool for bacterial genomes
- (2014) M. Kolmogorov et al. BIOINFORMATICS
- Escherichia coli ST131, an Intriguing Clonal Group
- (2014) M.-H. Nicolas-Chanoine et al. CLINICAL MICROBIOLOGY REVIEWS
- Incidence of bloodstream infection: a review of population-based studies
- (2013) K.B. Laupland CLINICAL MICROBIOLOGY AND INFECTION
- Virulence of Escherichia coli Clinical Isolates in a Murine Sepsis Model in Relation to Sequence Type ST131 Status, Fluoroquinolone Resistance, and Virulence Genotype
- (2012) James R. Johnson et al. INFECTION AND IMMUNITY
- Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis
- (2012) Wouter C. Rottier et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Identification of acquired antimicrobial resistance genes
- (2012) E. Zankari et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing
- (2012) Anton Bankevich et al. JOURNAL OF COMPUTATIONAL BIOLOGY
- Virulence Potential and Genomic Mapping of the Worldwide Clone Escherichia coli ST131
- (2012) Jean-Philippe Lavigne et al. PLoS One
- The ClermontEscherichia coliphylo-typing method revisited: improvement of specificity and detection of new phylo-groups
- (2012) Olivier Clermont et al. Environmental Microbiology Reports
- Bacteremia Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli Sequence Type ST131 and Non-ST131 Clones: Comparison of Demographic Data, Clinical Features, and Mortality
- (2011) Hsing-Chun Chung et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
- (2011) A.-P. Magiorakos et al. CLINICAL MICROBIOLOGY AND INFECTION
- Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features
- (2010) A. Courpon-Claudinon et al. CLINICAL MICROBIOLOGY AND INFECTION
- Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum β-lactamase-producing Escherichia coli
- (2010) Cheol-In Kang et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Meningitis Caused by Escherichia coli Producing TEM-52 Extended-Spectrum -Lactamase within an Extensive Outbreak in a Neonatal Ward: Epidemiological Investigation and Characterization of the Strain
- (2010) D. Moissenet et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Host Factors and Portal of Entry Outweigh Bacterial Determinants To Predict the Severity of Escherichia coli Bacteremia
- (2010) A. Lefort et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Molecular and Evolutionary Bases of Within-Patient Genotypic and Phenotypic Diversity in Escherichia coli Extraintestinal Infections
- (2010) Maxime Levert et al. PLoS Pathogens
- Community‐Onset Bacteremia Due to Extended‐Spectrum β‐Lactamase–ProducingEscherichia coli:Risk Factors and Prognosis
- (2009) Jesús Rodríguez‐Baño et al. CLINICAL INFECTIOUS DISEASES
- Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome
- (2007) R.J. Cordery et al. JOURNAL OF HOSPITAL INFECTION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started